Novavax partners get approval for Nuvaxovid targeting COVID-19 XFG variant for 2026-2027 season

Novavax's partners Sanofi and Takeda have secured approvals for the Nuvaxovid vaccine targeting the SARS-CoV-2 XFG variant for the 2026-2027 COVID-19 vaccination season in key markets including the U.S., EU, and Japan. This protein-based, non-mRNA vaccine offers a favorable tolerability profile, providing an important option for older adults and high-risk groups. Sanofi is expanding its marketing efforts in the U.S. and launching in new international markets, while Takeda maintains strong sales in Japan. Novavax will continue to earn royalties from these sales without direct commercial operations, supporting its business model and commitment to global public health.